5 Key Takeaways

• 1

  The BioTAK score helps distinguish takotsubo syndrome from acute coronary syndrome using blood-based biomarkers.

• 2

  The score was developed using data from 3,615 patients and validated in a separate cohort of 1,792 patients.

• 3

  BioTAK achieved an area under the curve of 0.97 in the development cohort and 0.93 in the validation cohort.

• 4

  A low BioTAK score indicates high sensitivity for ruling out takotsubo syndrome, while a high score alone is not diagnostic.

• 5

  The score is not intended to replace urgent coronary angiography and requires further validation for clinical implementation.